Literature DB >> 19965639

Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13.

Rachel T McGrath1, Thomas A J McKinnon, Barry Byrne, Richard O'Kennedy, Virginie Terraube, Emily McRae, Roger J S Preston, Mike A Laffan, James S O'Donnell.   

Abstract

von Willebrand factor (VWF) multimeric composition is regulated in plasma by ADAMTS13. VWF deglycosylation enhances proteolysis by ADAMTS13. In this study, the role of terminal sialic acid residues on VWF glycans in mediating proteolysis by ADAMTS13 was investigated. Quantification and distribution of VWF sialylation was examined by sequential digestion and high-performance liquid chromatography analysis. Total sialic acid expression on VWF was 167nmol/mg, of which the majority (80.1%) was present on N-linked glycan chains. Enzymatic desialylation of VWF by alpha2-3,6,8,9 neuraminidase (Neu-VWF) markedly impaired ADAMTS13-mediated VWF proteolysis. Neu-VWF collagen binding activity was reduced to 50% (+/- 14%) by ADAMTS13, compared with 11% (+/- 7%) for untreated VWF. Despite this, Neu-VWF exhibited increased susceptibility to other proteases, including trypsin, chymotrypsin, and cathepsin B. VWF expressing different blood groups exhibit altered ADAMTS13 proteolysis rates (O > or = B > A > or = AB). However, ABO blood group regulation of ADAMTS13 proteolysis was ablated on VWF desialylation, as both Neu-O-VWF and Neu-AB-VWF were cleaved by ADAMTS13 at identical rates. These novel data show that sialic acid protects VWF against proteolysis by serine and cysteine proteases but specifically enhances susceptibility to ADAMTS13 proteolysis. Quantitative variation in VWF sialylation therefore represents a key determinant of VWF multimeric composition and, as such, may be of pathophysiologic significance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965639     DOI: 10.1182/blood-2009-09-241547

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  The origin and function of platelet glycosyltransferases.

Authors:  Hans H Wandall; Viktoria Rumjantseva; Anne Louise Tølbøll Sørensen; Sunita Patel-Hett; Emma C Josefsson; Eric P Bennett; Joseph E Italiano; Henrik Clausen; John H Hartwig; Karin M Hoffmeister
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

2.  Investigating the influence of age, gender and ABO blood group on ADAMTS-13 antigen and activity levels in healthy Arabs.

Authors:  Anwar M Al-Awadhi; Seham K Al-Sharrah; Mehrez M Jadaon; Faisal Al-Sayegh
Journal:  Blood Transfus       Date:  2013-12-04       Impact factor: 3.443

Review 3.  ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis.

Authors:  Ming Zhong; Hanrui Zhang; John P Reilly; Jason D Chrisitie; Mayumi Ishihara; Tadahiro Kumagai; Parastoo Azadi; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

4.  A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria.

Authors:  Niamh O'Regan; Kristina Gegenbauer; Jamie M O'Sullivan; Sanaz Maleki; Teresa M Brophy; Niall Dalton; Alain Chion; Padraic G Fallon; Georges E Grau; Ulrich Budde; Owen P Smith; Alister G Craig; Roger J S Preston; James S O'Donnell
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

5.  Indian Bombay phenotype: it is different!

Authors:  Bipin Kulkarni; Ajit Gorakshakar; Vimala Singh; Anita Parihar; Ajay Donta; Harita Gogri; Seema Jadhav; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

6.  Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells.

Authors:  Sarah L King; Hiren J Joshi; Katrine T Schjoldager; Adnan Halim; Thomas D Madsen; Morten H Dziegiel; Anders Woetmann; Sergey Y Vakhrushev; Hans H Wandall
Journal:  Blood Adv       Date:  2017-02-23

7.  An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry.

Authors:  Ebtesam A Gashash; Arya Aloor; Dong Li; He Zhu; Xiao-Qian Xu; Cong Xiao; Junping Zhang; Aishwarya Parameswaran; Jing Song; Cheng Ma; Weidong Xiao; Peng George Wang
Journal:  J Proteome Res       Date:  2017-07-27       Impact factor: 4.466

8.  Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets.

Authors:  Yanfang Pan; Tadayuki Yago; Jianxin Fu; Brett Herzog; J Michael McDaniel; Padmaja Mehta-D'Souza; Xiaofeng Cai; Changgeng Ruan; Rodger P McEver; Christopher West; Kesheng Dai; Hong Chen; Lijun Xia
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

9.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

10.  Evidence of Endothelial Activation in Asymptomatic Plasmodium falciparum Parasitemia and Effect of Blood Group on Levels of von Willebrand Factor in Malaria.

Authors:  Gregory S Park; Kathleen F Ireland; Robert O Opoka; Chandy C John
Journal:  J Pediatric Infect Dis Soc       Date:  2012-03-01       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.